Micvotabart pelidotin

Antibody–drug conjugate

Also known as PYX-201

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: data expected December 2026 (Pyxis Oncology, 5 Nov 2026). “We plan to provide a corporate update in December 2026 that we expect will outline a comprehensive development strategy for MICVO in R/M HNSCC, including how emerging combination data inform potential opportunities across treatment settings, and will include updated efficacy and safety data from the ongoing PYX-201-102 Phase 1/2 dose escalation study evaluating MICVO in combination with KEYTRUDA ® (pembrolizumab) across multiple doses in 1L R/M HNSCC.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Solid Tumors
Phase 1 (1)
Solid Tumors
NCT05720117 · Pyxis Oncology, Inc
2023-03-14 – 2028-06-30 · Solid Tumor, Advanced Solid Tumor
What this study did

Competitive landscape

This drug's own stage for Solid Tumors: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Micvotabart Pelidotin: this drugPhase 1/2Antibody–drug conjugateED-B domain of fibronectinnot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Weak signalNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETnot yet gradedNo reviewed efficacy summary in this indication
ALG.APV-527Phase 1/2Multispecific antibody4-1BB (CD137) x 5T4not yet gradedNo reviewed efficacy summary in this indication
CR-001
Phase 1/2(overall)
Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cell therapyTumor antigen menu (TROP2, MSLN, B7-H3, HER2)not yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Single-Target CAR-NK CellsPhase 1/2Cell therapyPersonalized, biomarker-guided allogeneic chimeric antigen receptornot yet gradedNo reviewed efficacy summary in this indication
Linebacker
—(overall)
Small moleculePIM kinases (PIM1/2/3)not yet gradedNo reviewed efficacy summary in this indication
RP3DiscontinuedOncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Micvotabart pelidotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-04-25 · NCT05720117 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-12-06 · NCT06795412 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2026Topline resultPhase 1 monotherapy in 2L+ R/M HNSCC: 36% confirmed ORR (n=33)
US · Pyxis Oncology · Source ↗